{"3fe09fafae1c4200bf36faea155c3c62": "helix <unk>", "354a06365eb5430db7d04eb6bea5af55": "<unk> polymerase <unk>", "1126a2a0c1ae4863844e2b5cc811f042": "<unk>acillus subtilis", "1e1ef110e6154949bc822e542fff38e2": "[CLS]", "344f79431db040ea8cbbb6cb3a1b171a": "<unk>ibrillar <unk>-synuclein (<unk>-<unk>yn)", "ba84f91cf9b6461d9ee02be446bcdffc": "<unk>hediak-<unk>igashi syndrome", "e4f9aab09e074c42b56d239bd1ea6bf9": "a common 7<unk> <unk>-derived retroposing monomeric element", "db3d5700fb404c9d9b22de58652e441b": "[CLS]", "f69aed865e4f4461b59e86ff393595b6": "<unk>estless legs syndrome (<unk>),", "23231ba1735c46b7b4dbacd35b95a111": "<unk>utations in rfx6", "d99ab786d2ec4d17b1540cf721370ef0": "<unk>e", "c56e3d34c08a4d009fb83d8ed37c636a": "<unk>he", "ad2342b8121d4fafa653d33df74f5afc": "restless legs syndrome", "071541cdeb9e4d6c9a4b372f6a11c778": "pneumonia", "83d7f282309948759aa19ff5ddcdd45c": "<unk>wo", "c35f27d4167846e1adc3aadd2981e4dc": "<unk> symptoms", "767ca74416ef41738a08d2aef5208410": "<unk>lumazenil", "b5b0517d354847768bfb0266b7052a80": "<unk> gene", "30982bbba290475cadfbcc0116b0d9c4": "<unk> gene mutation", "fdc8771a13204b6eb28d48a0e3f1d6c5": "<unk>ox<unk>1 and <unk>ox<unk>1", "d6e9cee2def349948db2eae4577d1aaa": "dabigatran", "ae5bb34ab378486298ab61b3973ece7b": "intron 1", "89d94b385eb34bc8ba92ccfb2605442f": "alpha-synuclein", "09a953250a1f4db4816c782183c4fa89": "[CLS]", "9c678887061c48e688347d3c09889e6c": "<unk>he chrom<unk>raw", "f33d6fecbf754206bd68d7fc7adad530": "", "2218c4979008424a9f948a7b71448a42": "restless legs syndrome", "e20b24502922481885eab94b612f374d": "malaria", "fda25d478d054f8bb5e7cf002113e5e8": "resilience", "34757c8e5ca444a192856060543f7791": "autosomal dominant inheritance", "6e6cc6752f9047989d4703ae6d6c8051": "flumazenil", "b37db289ef2948e9b5e75fbc0cbd66bf": "antiparallel", "353a222964794361bdaaf8ea481c12ee": "(<unk>3/<unk>),", "354f714bfea84f6b8e02e7acba3f7d67": "(<unk>1)", "67b5647fc6814b5d880a3bc12a5c419c": "(<unk> [1])", "4499cb8591df4db39618e8fc1992e197": "[CLS]", "47da715dad124f3690dc1764042458cc": "", "db97a187c75442e883f177344a687937": "[CLS]", "5389373ddbe048119c1dbeb0494dd528": "", "4504ae5e0d41435984b259c276b8cf7f": "<unk>-<unk>ynuclein", "4b0eb00ff2664722917b55ccb33b9689": "tuberculosis", "d4ee2e1fb7364cd6bb5931d72186c5bb": "<unk>esmosomes", "9305f4338a854725ab83e9b81c3c35b4": "(gas outlining the falciform ligament", "98e46197609848b39e1fb5db6b9f7fa8": "<unk>-synuclein (<unk>yn),", "6c15c6c5007f4bac9ec1454df2719dfa": "dabigatran", "179e834f3f064c7188755ef9596db9d9": "<unk>he", "92d38fcd3d864c5aa90a01fe0e5787f2": "dabigatran", "842999d9925347eca644cb9699a36b65": "<unk>he protein alpha-synuclein", "a9c0c53d05f1474083e2f1ad8ea28756": "sexual transmission of <unk>", "7161d325e39f4f4884391fb5e3adb5db": "(<unk>er129)", "39ab6d3436864e6ea8cc1a577a441db5": "<unk>denosine deaminases", "26694e93ebbc4962895a9d5377a2e4e8": "autosomal recessive pattern", "66854406960a4a4ba4cff23625202de8": "[CLS]", "85a18e64fb2d47b0afeee4832c599891": "<unk>he <unk>/<unk> gene fusion, the hallmark of chronic myelogenous leukemia (<unk>) is generated in 2-10% of patients by a variant <unk>h translocation", "c3272be6bdea40c9ac22dfe5337dc311": "(<unk>2) gene", "7b387c3302ca4a718ed588d6618acea4": "<unk>hediak-<unk>igashi syndrome", "792b104e025543b5b32f47d3bb1b5c44": "antiparallel", "62dfb0f0049641648b339a94e27b7262": "vivax", "0c06ab7dd90c4dad83de126afa2b4101": "[CLS]", "3624fe9b9dca47c98be7dc8c2d2db870": "027", "072774d22d1943ada30195f317483bf3": "[CLS]", "0c2e363266584674a6c79cd1c7d3e1eb": "", "d451ee65e0e14baaa98a29b68092c5fc": "<unk>azex syndrome", "d8dc6dcb02604df98e1a216e74a229fa": "<unk>he <unk>otos syndrome gene product, <unk>1", "e7dd43f614bd4a44808e13eb2dbde1f6": "[CLS]", "7612f12628274b6dbdc14d2f9a22855f": "non-specific in patients with stress urinary incontinence", "c83c84f9c33345268a80de699a70104f": "[CLS]", "8cb2d5ed371845bdbc1aef1bc23e2418": "alpha-synuclein", "a02c851b01e7465280df78b10bd835f5": "ventral intermediate thalamic nucleus", "3216ab3e241a45eea283765e3bee89ef": "<unk>ron deficiency", "b7441dc6481f4a8c8ea767fe70d618bb": "<unk>3/6 phosphatase. <unk>owever, while anisomycin treatment of cells leads to <unk>3/6 protein degradation, arsenite appears to inactivate <unk>3/6 directly", "8879689c14314feb9629e3d724500547": "[CLS] <unk>hat does the <unk> complex acronym stands for?[SEP] <unk>ccurate cell division requires the proper assembly of high-order septin structures. <unk>n fission yeast (<unk>chizosaccharomyces pombe),", "13712b1db9094ec2bd023d0036495b5d": "<unk>azex syndrome,", "817590b6c9a647a5aef10b85199aef9b": "spleen tyrosine kinase", "f252703de7194f1983547f4bf860ba40": "<unk> gene", "1943cdaa336f472f827be07ba6e57bb5": "<unk>-<unk>ynuclein", "464136c1262c4537a73e251dcc6d6f54": "[CLS]", "513ee6b7112740b7afa36d176c0f833f": "[CLS]", "08f0df88d96347d39f79a425ef636d4b": "027", "88255af0d4234ad09cdee7305967cf18": "[CLS]", "6f535f0663104aabbe0325e73769505f": "<unk>he antiparallel", "4688b81a249a4edd87b46d5ce300cfcf": "<unk>amp2a", "8708371a1d3b41c89c378772ccbe6fb2": "<unk>", "f39ba0ef13d74fbbbee6b6a7495a7da1": "posttraumatic stress disorder", "d6994d74aee440879b8c68ca849fa9db": "<unk>he <unk>hediak-<unk>igashi syndrome", "34689931e2824bf58d7aa234d7a4eed3": "48", "9bf503906c3b425bb54cf156d27e9101": "<unk>ac1", "3a09c991f94d49ac9f85560e9ef63b8f": "<unk>he <unk> <unk> correlated significantly with <unk>ot<unk>harp in women", "cecd920cbb724d98aaf99c70c2dcc371": "", "657d5d7eecf249cb96e36f5b3a818fcf": "alpha-<unk>ynuclein", "a4da3f3b9ad440b69aaf79b7d6f6f893": "<unk>lpha-synuclein", "e29d0b192b44413e95a08a2afa14fcbc": "zfhz1b", "04cb5e56a4624e849a6e56966d0d643e": "", "2955684affa14660b9c3b54689b9b2d2": "<unk>he ubiquitin ligase <unk>1", "08994280294d46b78596738f2a8bd39a": "[CLS]", "a41b67e4e4004aa6a155ea9bb5d45fc4": "<unk>his increase was more pronounced in male than in female patients", "84268ced61744024a40b6f8d2316d275": "alpha-<unk>ynuclein", "bba18f5535f945b98b8a82421bcbe956": "posttraumatic stress disorder", "da32f12980d845719c03c2c03494afe1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "ba508f5b8dfb4fbc83ecf9831706b686": "<unk>1<unk>", "c24c1289233c489691969ee391245427": "[CLS]", "d74834afd23a4192b6b88ed137c2ea87": "[CLS]", "e3fcd872a2a34c279d4633b77cd0d266": "<unk>he <unk>1 gene", "ccaf40e8947045dbb86dafd325b2f626": "[CLS]", "0bede4582a9e40d4bb498c8ee7d6c64e": "<unk>iamond-<unk>lackfan anemia", "141c4f0d6d4d4916a34c9dae06adcc8a": "<unk>9<unk>6 gene", "7ff12940e9c34f73936d58aa6f5f4f8b": "<unk> gene", "412a49803a00424099cd84a75d92bd63": "", "df45d243d5b846c9b8dd26f62bbe479e": "formin", "4f93de9591b34369ba45f43f3f6efb52": "restless legs syndrome", "fb6050311b794585986ab4a8b17b564e": "", "61ec5684d44c4296809c466509051021": "dasatinib inhibits <unk>-mediated signal transduction, cellular proliferation", "16a25da84839436a89074d9ddedd979f": "<unk>estless <unk>egs <unk>yndrome", "3edca0aa7f0d4e7fba97191c13e28d28": "(<unk>d<unk>)", "ae333a083631463086544ba27a982cf1": "[CLS]", "7bd8a7a1bafe47c3abd747f77a580738": "<unk>otion of the median nerve", "2d73138d00bc4dfc99e39ba6f78babb8": "iron deficiency", "7bc7d50257d34f87ab4fb5cf15488ef8": "deleterious mutations", "513f317b2bbb49a488431854ec8b1291": "[CLS]", "5658da3cc5b84d219d6f6991552febf0": "[CLS]", "9095328339f447188880bc5412e035d4": "<unk>1<unk> gene", "b2f73e6827624d46a50622245bc0bc8c": "<unk>3", "24a13e3726da44deb5ad15627d9c04f8": "[CLS]", "33f0175a3dd1410a979d8698198ca39b": "", "d38d490c5d9f45a0818bec552463879b": "<unk>very 6 <unk>onths", "3dff550077ca471a8137430b2d11722c": "[CLS]", "ccb9b1d3df6f45b2bb19557def943330": "<unk>his phase <unk> study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. <unk>atients (<unk>=1347)", "f129d78a420746cd9b0364aa8ac1fa28": "", "1bcd341d9896445e8554027ad01ed066": "alpha-proteobacterium", "91ba5f0e9cdb420b8e49daf63935d388": "<unk>-galactosidase", "204004adaf394da29332aa0a6d83a243": "woolly hair", "976535f8681e45c9881400b1e940a908": "", "34237e2593fe47159c2577f4c10f4577": "malaria", "86bd299403624adfa79bf2ac1de79528": "", "a599caa6467c4126af22518a18e24c41": "[CLS]", "ea59c7ee76424a47bdecc74c9987666f": "[CLS]", "55f7e26b1a6a41c08f110ecb1c372358": "early", "b0c5cb7e458c48f9a369b023a6f154ef": "<unk>he <unk> recognition motifs of <unk>-1 are linked to a glutamine-rich prion-related domain", "d053f9773d0649b8b2acea49e06af19f": "<unk>he", "e37eef543acc42c0902146dfb8efe1c7": "[CLS]", "8e8bc2fb6f4f494c94d828de7c279203": "alpha-amanitin", "f40c5ca38b964c3fbfd353444320a3b9": "48", "1c5db62efbc145768b9fd53df6a404d5": "increased expression of <unk>2", "66ed19703ab9429588260046aacc2ac1": "<unk>9<unk>6", "2b04e73544f7459d9232316ec0e13a4a": "<unk>ivolumab was developed as a monoclonal antibody against programmed death receptor-1", "9017897d71c2434d90f474f17544eebd": "(<unk>ox)", "dd55ff8b09a7433aa467295dae5b0c62": "<unk>isease patterns in <unk> vary between the sexes; the condition is more commonly seen in women", "54d034854e514d05b8be8c343c9d0484": "[CLS]", "2f91c196e1e14427999116eb471acf92": "", "ee5c985a3d3b4cd89647bbe76b8def7b": "", "c52217c869064579a2201e621fdbf60c": "(<unk>3<unk>4)", "6058f2f8356844f09683a30ad50f344f": "[CLS]", "6c9b255f11a04caa992ae6ef8de912b0": "autosomal", "d30650e611f64f46abbf5b525ce53a92": "<unk>ight-harvesting pigment-protein complex of <unk>hotosystem <unk>", "efb13b867d664aa1b52ab77cba850165": "soft connective tissues", "5c2cbb8eaf4742919bc8a56682ea0e5a": "(<unk>)", "c9db9e67e67b4c408b9e053169e05a70": "(<unk>1)", "69c3caa799bb4990932019ccbabd967e": "alpha-synuclein", "2a8c06afe76f42f9ab06708b3adc27fc": "<unk>he apolipoprotein <unk> type 4 allele is a susceptibility gene for late-onset <unk>lzheimer's disease. <unk>polipoprotein <unk> is found in neurons, some of which contain paired helical filaments made of the microtubule-associated protein tau. <unk>revious studies have demonstrated that the apo<unk>3", "15acdfafb8db4713a4ed63acfd61cd30": "[CLS]", "966b0a95d1b84227ac890a3daaef2086": "<unk>he molecular functions", "a118373d91094ae6aca3047edf9b0bac": "", "6a92b3312fe9468e9d709a8e59c9fadc": "facioscapulohumeral muscular dystrophy", "72c14e2563a94713baea221bbf150180": "<unk>lasmodium spp.", "f9b282fbb19a4becb10efa8009e39d88": "[CLS]", "3005311091144dfdb1464aeae598c703": "alpha<unk> protein fibrils", "2cf9e36ee549421b84170a93d439b69d": "<unk>1", "c5f738e45b874642afbdf22cb1b0c970": "enhancers", "4edb95a363144efdb21977cc7f1912a8": "[CLS]", "30f3fe33aa974d54aa12ad555cb22644": "[CLS]", "930ebd41e49942059fff966207ce5c03": "community acquired pneumonia", "9bb5d9f90f804b34971f0a239f63343b": "", "52cd8f90006a41c999627c367f252ff3": "[CLS]", "5fd7a2dfb5344090b95d6ffff8d1456c": "<unk> gene", "169d1ca25e78425dbd60b6192286d3dd": "<unk>-<unk>", "785d411170fb461891f9aaf5794d8c28": "riociguat", "70d7878277804532b313a72e5e20e286": "naloxone", "77c8c610c2b44cfdadd28ce51c2e8c6b": "[CLS]", "f1bd012a42904b12a152b624439f2533": "<unk>matinib mesylate", "51a1889816af46d0bc6c17f5001e75f4": "(<unk>h(+))", "251f6ff810384420b6df79a29f772ff0": "ouabain", "e9f8a67168b34db5ab3343fb3e9136ae": "[CLS]", "020cf00b943b468f9e50ce04bee47b9f": "ubiquilin 2", "c13bddb9e37b47c69428caa895cea7ae": "<unk>illis-<unk>kbom disease/restless legs syndrome", "0c569438ed394a3b9e7d3c5ed7abd507": "[CLS]", "ec3c96601d8840c58a8302933740c8a2": "[CLS]", "e1caec128d5f4cb4a20159f0430b80d1": "", "704744227c8048f0b703848334d6ec87": "<unk>-domain", "4a2d924caf4d464aa5a7837b4e6e320d": "alpha-synuclein", "a26bb24d46114aeaa1d54858c6340119": "<unk>-synuclein", "a9464ddc76874f33bc3080db5c5c07b9": "", "9bcff955534e462aad930acfdb1fef0c": "<unk>9<unk>6", "cf97c5fcf3d94305a47f705ecb7271f5": "<unk>lpha-synuclein (<unk>-<unk>yn)", "fd51aa90ceb147e78cd27c4328ac7962": "[CLS]", "2406a794568840628014804927e40975": "craniosynostosis", "f86ef5e1ac664cb0a799f69a2e54f94d": "iron deficiency in the brain has been observed on imaging and cerebrospinal fluid analyses of patients with <unk>. <unk>n contrast, the results of neuroimaging studies evaluating brain dopaminergic functions in patients with <unk> have yielded inconclusive results, although involvement of the hypothalamus (<unk>11)", "d298832c62de4e73ad3b013ea2443d51": "(<unk>2) inhibitor that inhibits renal glucose reabsorption", "432d404973ba41318c6fe93752543d01": "active tuberculosis", "2c1bd1c29737403c884ad051c6440ed5": "[CLS]", "4bcc2386dcef433497f13c0ffbc668e1": "<unk>iroids", "3f7b340bb0f840e98a015f2346104288": "<unk>he evolutionarily conserved <unk> domain", "bd9c8ec49b8446ba9d107c61a8280a06": "[CLS]", "c3236d984bae4fe9a702753a63371250": "<unk>120-<unk>147681", "cdc42c838604450c83009db175c03137": "<unk>he <unk>", "0e17fa4dc2be4a299e36c5cf49b2fbee": "<unk>3/6 (<unk>8)", "c5bec275c58b4f4e81b005aac5c0e82f": "<unk>orynebacterium minutissimum", "cc706a937ac44341a23ae0cae23e2bdd": "", "9cce10bf0b6546509cf2de1aba61138e": "<unk>estless legs syndrome", "7b813fb8fbe444c2b8ed096bcfc51ca6": "posttraumatic stress disorder", "09ebf96c823548e9a0908cc35606cc13": "<unk>yk", "0e24607baaa74369a7171110551ca197": "<unk>gfr3 gene", "151aa629d0054dd180576c092fb49055": "[CLS]", "84150498c316405889993b5f785ce213": "<unk>po<unk>4", "d161b97805de4abe9ce8e5aff755c987": "adenine phosphoribosyltransferase (<unk>) locus, in either a transcribed or nontranscribed <unk> gene (1)", "49df234dddfb4af6b70443ee0df3e00d": "<unk>lpha-synuclein (alpha<unk>)", "7eb603c02b0c40579e66fe97ee76c19f": "", "fc6f88c8ca2e451284d7c33fa8b5071a": "", "0cf3e09ca48743ab8afcd531f7b306e9": "antiparallel dimers", "a5597097671740739398b8d4cab19549": "[CLS]", "682f059c5e1247ec92d678ce3cc5a4cc": "<unk> gene", "21b8aedf45d248998d7f1fe63ff3f685": "(<unk>1) gene", "d691510d9c1e401ebf6364b876537b48": "chromosome 14", "6960bdbb74c3432a83bd3a3c0a6c30f1": "<unk>", "289d6353e4064a62a58db9f9192b3eff": "<unk>estless legs syndrome/<unk>illis", "0460fc84d839453e88d73ec2691da940": "<unk>pstein-<unk>arr virus", "18b6217da1e544f0816a04e6db73ff7d": "cysteine", "ec3fbfeea1b541fd86801d3f230fe7ac": "alpha-synuclein", "ee2bb6f12fef47d0a3ddeb7d9f328f4d": "<unk> is a myeloproliferative disorder characterized by the presence of the <unk>hiladelphia chromosome or the <unk>-<unk> fusion oncogene", "0852624d3eb84ea89be6dce27c79703c": "flumazenil", "746d6125a1ae4b47b8868da9703ff04b": "[CLS]", "220f2fda6f7b4ca1a8b1ce1ca1c93bb3": "", "dabfffc898254535a9a607a6650d2562": "cysteine", "edddbb8cad694d9a8b64e23dfb8292ba": "tyrosine kinase", "f1f7239d2a0c4cb885c35010f04d0b4a": "[CLS]", "d4042c8ae89c41c5b5b34e283593ecf2": "iron deficiency", "fd6f4f8657ba4d22a07d09f21a98e576": "<unk>-<unk> tyrosine kinase is the critical pathogenetic event in <unk>", "f60eb4dfa5774b8c8a56567d0989deff": "", "db82e6a831de4a5e9ce53368a088128a": "<unk>pidermal growth factor receptor", "78d3a470a5fc433fb380a0e051deb39c": "[CLS]", "7aee0395db2b4a49bbecaa0dd253b366": "7<unk> <unk> gene", "8d3460a44ce34647a536fc55cd18a4e1": "", "e77f03a3c71044b98123b465164c6cc7": "<unk>a+-<unk>a2+ exchanger (<unk>) was investigated and compared against that of 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea (<unk>-<unk>7943). <unk>n addition, the effects of <unk>0400 on reperfusion injury in vitro and in vivo were examined. <unk>0400 was extremely more potent than <unk>-<unk>7943 in inhibiting <unk>a+-dependent <unk>a2+ uptake in cultured neurons, astrocytes, and microglia: <unk>50s of <unk>0400 and <unk>-<unk>7943 were 5 to 33 n<unk> and 2 to 4 micro<unk>, respectively. <unk>0400 at the concentration range that inhibited <unk> exhibited negligible affinities for the <unk>a2+ channels, <unk>a+ channels, <unk>+ channels, norepinephrine transporter, and 14 receptors, and did not affect the activities of the <unk>a+/<unk>+ exchanger, <unk>a+,<unk>+-<unk>ase, <unk>a2+-<unk>ase, and five enzymes. <unk>0400, unlike <unk>-<unk>7943, did not inhibit the store-operated <unk>a2+ entry in cultured astrocytes. <unk>0400 attenuated dose- dependently paradoxical <unk>a2+ challenge-induced production of reactive oxygen species, <unk> ladder formation, and nuclear condensation in cultured astrocytes, whereas it did not affect thapsigargin-induced cell injury. <unk>urthermore, administration of <unk>0400 reduced infarct volumes after a transient middle cerebral artery occlusion in rat cerebral cortex and striatum. <unk>hese results indicate that <unk>0400 is the most potent and selective inhibitor of <unk>", "78f0c50b8c6849b2859237d4e919f8cd": "[CLS]", "f00ef1233f084ed28b6eacd36aca14d6": "(<unk>).", "64a4ffe678aa497da235a1cde7d5712e": "congenital malformations", "a40ec3c2b8dd4fa4a955eb489be36aa0": "autosomal-dominant disorder", "1a4946e6636c4ab3a37f421bb4397409": "atrial fibrillation and flutter", "85af34b4c81f4eee8ca3336339fad285": "congenital erythroblastopenia", "c09b13353ce8449cae19747d33b78dc2": "(double homeobox 4)", "85b37fa6f6cb4803bcf4aa988b62bbac": "", "10848a4c98c7472199863319754dae63": "<unk>"}